News & Insights

Markets
GSK

Hikma Resumes Launch Of Generic Version Of GlaxoSmithKline's Advair Diskus In U.S.

April 21, 2021 — 02:37 am EDT

Written by RTTNews.com for RTTNews ->

(RTTNews) - Hikma Pharmaceuticals Plc. (HIK, HIK.L) said that it has resumed the launch of its generic version of GlaxoSmithKline's Advair Diskus in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021.

Hikma noted that it will immediately resume launch activities of its generic product for Advair Diskus, 100mcg/50mcg and 250mcg/50mcg doses in the US.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source ->

Stocks mentioned

GSK

More Related Articles

Info icon

This data feed is not available at this time.

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.